D.A. Davidson & CO. Sells 774 Shares of Axon Enterprise, Inc $AXON

Key Points

• D.A. Davidson & Co. reduced its stake in Axon Enterprise, Inc by 8.3%, now holding 8,561 shares valued at approximately $7.09 million after selling 774 shares in the second quarter.
• Bank of America has raised its price target on Axon Enterprise from $895 to $1,000, with the company receiving strong buy ratings from multiple analysts.
• Insider transactions revealed that President Joshua Isner sold 15,919 shares in August, worth about $11.88 million, which represents a decrease of 6.26% in his position.

D.A. Davidson & CO. cut its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 8.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,561 shares of the biotechnology company's stock after selling 774 shares during the quarter. D.A. Davidson & CO.'s holdings in Axon Enterprise were worth $7,088,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. LaSalle St. Investment Advisors LLC grew its holdings in shares of Axon Enterprise by 2.1% during the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company's stock valued at $408,000 after purchasing an additional 16 shares during the last quarter. Hemington Wealth Management grew its holdings in shares of Axon Enterprise by 70.8% during the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 17 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Axon Enterprise by 5.0% during the 1st quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company's stock valued at $203,000 after purchasing an additional 18 shares during the last quarter. WCM Investment Management LLC grew its holdings in shares of Axon Enterprise by 0.8% during the 1st quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company's stock valued at $1,306,000 after purchasing an additional 19 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC grew its holdings in shares of Axon Enterprise by 0.5% during the 1st quarter. Sheaff Brock Investment Advisors LLC now owns 3,561 shares of the biotechnology company's stock valued at $1,873,000 after purchasing an additional 19 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on AXON. Bank of America lifted their price target on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Weiss Ratings reissued a "hold (c)" rating on shares of Axon Enterprise in a report on Wednesday, October 8th. Wolfe Research started coverage on shares of Axon Enterprise in a report on Monday, July 7th. They set an "outperform" rating on the stock. JMP Securities reissued a "market outperform" rating and set a $825.00 target price on shares of Axon Enterprise in a report on Monday, September 29th. Finally, Craig Hallum raised shares of Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 target price on the stock in a report on Tuesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Axon Enterprise has a consensus rating of "Moderate Buy" and a consensus target price of $841.64.

Insider Transactions at Axon Enterprise

In other news, President Joshua Isner sold 15,919 shares of the business's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the transaction, the president owned 238,379 shares in the company, valued at approximately $177,892,712.54. The trade was a 6.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Brittany Bagley sold 5,000 shares of the business's stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the completion of the transaction, the chief financial officer owned 93,592 shares in the company, valued at $66,813,456.96. This trade represents a 5.07% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 59,932 shares of company stock worth $45,115,616. Company insiders own 4.40% of the company's stock.

Axon Enterprise Trading Up 2.2%

AXON opened at $716.39 on Friday. Axon Enterprise, Inc has a fifty-two week low of $422.38 and a fifty-two week high of $885.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The firm has a market capitalization of $56.24 billion, a price-to-earnings ratio of 176.89, a PEG ratio of 27.23 and a beta of 1.41. The company's 50 day moving average price is $733.54 and its two-hundred day moving average price is $722.15.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company's revenue for the quarter was up 32.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.